HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical aspects of uterine sarcomas (author's transl)].

Abstract
Uterine sarcomas constitute 1% to 3% of all uterine cancers. There are three main histological varieties: endometrial stromal sarcoma, leiomyosarcoma, and mixed mesodermal (Müllerian) sarcoma. The tumors are characterized by local aggressiveness and early dissemination. According to the literature, 5 year survival rates range from 3 to 75% (!). This wide range reflects great prognostic differences in the various histologic types. On the other hand it may be due to discrepancies in histopathological evaluation. Radical surgery is the most effective therapy. In early stages it leads to 5 year survival rates of up to 88%. Adjuvant irradiation may increase the control of disease in the pelvis but has proven to be of little influence on the final outcome. The histologic variants show great differences in radiosensitivity. In endometrial stromal sarcomas adjuvant radiation therapy apparently can improve the treatment results. By contrast mixed mesodermal sarcomas are highly radioresistent. There is poor knowledge on the effectiveness of cytotoxic agents on uterine sarcomas. Objective remission of distant metastasis has been observed following treatment with cytotoxic antibiotics (Adriamycin).
AuthorsH E Stegner
JournalPathology, research and practice (Pathol Res Pract) Vol. 169 Issue 2 Pg. 120-6 (Oct 1980) ISSN: 0344-0338 [Print] Germany
Vernacular TitleKlinik der Uterussarkome.
PMID7443570 (Publication Type: English Abstract, Journal Article)
Topics
  • Adult
  • Age Factors
  • Aged
  • Female
  • Follow-Up Studies
  • Humans
  • Leiomyosarcoma (therapy)
  • Middle Aged
  • Prognosis
  • Sarcoma (pathology, surgery, therapy)
  • Uterine Neoplasms (pathology, surgery, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: